Previous infection with Chlamydia pneumoniae and long-term prognosis in patients acute coronary syndrome and with non-ST segment elevation;Infección previa por Chlamydia pneumoniae y pronóstico a largo plazo en pacientes con síndrome coronario agudo sin elevación del segmento ST

Medicina Clinica

Volumn 124, Issue 18, 2005, Pages 681-685

  Sionis, Alessandro ^a   Bosch, Xavier ^a,b   Marín, José L ^a   Anguera, Ignaci ^a   Hage, Marta ^a   Bórquez, Emiliano ^a   Verbal, Fernando ^a   Vidal, Josep ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Acute coronary syndrome; Chlamydia pneumoniae; Infection; Mortality; Myocordial infarction; Prognosis; Unstable angina

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY;

ACUTE HEART FAILURE; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; HEART DISEASE; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RISK ASSESSMENT; SERODIAGNOSIS; ST SEGMENT ELEVATION;

EID: 21244478677     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13075089     Document Type: Article

References (28)

1. Ross R. Atherosclerosis. An inflammatory disease. N Engl J Med. 1999;340:115-26.
2. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-97.
3. Ridker PM. On evolutionary biology, inflammation, infection, and the causes of atherosclerosis. Circulation. 2002;105:2-4.
4. Mattila KJ, Valtonen W, Nieminen M, Huttunen JK. Dental infection and the risk of new coronary events: prospective-study of patients with documented coronary artery disease. Clin Infect Dis. 1995;20:588-92.
5. Fernández-Miranda C, Paz M, Aranda JL, Fuertes A, Gómez de la Cámara A. Infección crónica por Chlamydia pneumoniae en pacientes con enferrnedad coronaria. Relación con el incremento de los valores de fibrinógeno. Med Clin (Barc). 2002;119:561-4.
6. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation. 1997;96:4095-103.
7. Kalayoglu MV, Libby P, Byrne GI. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA. 2002;288:2724-31.
8. Bloemenkamp DG, Mali WP, Visseren FL, Van der Graaf Y. Meta-analysis of sero-epidemiologic studies of the relation between Chlamydia pneumoniae and atherosclerosis: does study design influence results? Am Heart J. 2003;145:409-17.
9. Muhlestein JB, Hammond EH, Carlquist JF, Radicke E, Thomson MJ, Karagounis LA, et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerosis versus other forms of cardiovascular disease. J Am Coil Cardiol. 1996;27: 1555-61.
10. Bennejo García J, Martínez Martinez P, Martín Rodríguez JF, De la Torre Carpente M, Bustamante Bustamante R, Guerrero Peral AB, et al. Inflamación e infección en la enfermedad coronaria estable y en el síndrome coronario agudo. Rev Esp Cardiol. 2001;54:453-9.
11. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96:404-7.
12. O'Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA. 2003;290:1459-66.
13. Zairis MN, Papadaki OA, Psarogianni PK, Thoma MA, Andrikopoulos GK, Batika PC, et al. Serologic markers of persistent Chlamydia pneumonias infection and long-term prognosis after succesful coronary stenting. Am Heart J. 2003;146:1082-9.
14. Zhou YF, Csako G, Grayston JT, Wang S, Yu ZX, Shou M, et al. Lack of association of restenosis following coronary angioplasty with elevated C-reactive protein levels or seropositivity to Chlamydia pneumoniae. Am J Cardiol. 1999;84:595-7.
15. Prazeres da Costa C, Neumann FJ, Kastrati A, Stallforth I, Schmid M, Joghetai N, et al. Role of IgG-seropositivity to Chlamydia pneumoniae in early thrombotic events after coronary stent placement. Atherosclerosis. 2003;166:171-6.
16. Toss H, Gnarpe J, Gnarpe H, Siegbahn A, Lindahl B, Wallentin L. Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease. Eur Heart J. 1998;19:570-7.
17. Chousat R, Montalescot G, Collet JP, Jardel C, Ankri A, Fillet AM, et al. Effect of prior exposure to Chlamydia pneumonias, Helicobacter pylori, or Cytomegalovirus on the degree of inflammation and one-year prognosis of patients with unstable angina pectoris or non-Q-wave acute myocardial infarction. Am J Cardiol. 2000;86:379-84.
18. Kähler J, Gerth S, Schäfer P, Boersma E, Köster R, Terres W, et al. Antibodies to Chlamydial lipopolysaccharides in unstable angina pectoris. Am J Cardiol. 2001;87:1150-3.
19. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycln in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J. 1999;20:121-7.
20. Sinisalo J, Mattila K, Valtonen V, Anttonen O, Juvonen J, Melin J, et al. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-Q-wave coronary syndrome. Circulation. 2002;105:1555-60.
21. Zahn R, Schneider S, Frilling S, Tebbe U, Weber M, Gottwik M, et al. Antibiotic therapy after acute myocardial infarction. A prospective randomized study. Circulation. 2003;107:1253-9.
22. Stone AF, Mendall MA, Kaski JC, Edger TM, Risley P, Poloniecki J, et al. Effect of treatment for Chlamydia pneumonias and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation. 2002;106:1219-23.
23. Cercek B, Shah PK, Noc M, Zahger D, Zeymer U, Matetzky S, et al. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet. 2003;361:809-13.
24. Wang SP, Grayston JT. Microimmunofluorescence serology in Chlamydia trachomatis. En: De la Maza LM, editor. The 1983 International Symposium on Medical Virology. New York: Elsevier Science; 1984. p. 87-118.
25. Prasad A, Zhu J, Halcox JP, Waclawiw MA, Epstein SE, Quyyumi AA. Predisposition to atherosclerosis by infection: role of endotelial dysfunction. Circulation. 2002;106:184-90.
26. Sander D, Winbeck K, Klingelhöfer J, Tejen T, Conrad B. Progression of early carotid atherosclerosis is only temporarily reduced after antibiotic treatment of Chlamydia pneumoniae seropositivity. Circulation. 2004;109:1010-5.
27. Neumann FJ. Chlamydia pneumoniae-atherosclerosis link: A sound concept in search for clinical relevance. Circulation. 2002;106:2414-6.
28. Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Rippin G, et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation 2002;105: 15-21.